Clinical Trials Browser

Phase 3 × abemaciclib × Breast × Clear all

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

Phase 3 Active not recruiting

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT05696626 2026-01-26

ELAINEIII

Phase 3 Recruiting

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

Phase 3 Active not recruiting

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04584853 2026-01-14

POETIC-A

Phase 3 Active not recruiting

Breast Cancer Female

NCT02107703 2025-10-21

MONARCH 2

Phase 3 Active not recruiting

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT07190443 2025-09-29

AURA

Phase 3 Recruiting

Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04752332 2025-07-15

eMonarcHER

Phase 3 Terminated

111 enrolled 9 charts

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

Breast Neoplasms

NCT03155997 2025-04-20

monarchE

Phase 3 Active not recruiting

5,637 enrolled 12 charts 2 FDA

Breast Neoplasms

NCT06341621 2024-04-10

Rainbow

Phase 3 Recruiting

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms